Abstract: The invention relates to a method of producing the radiolabeled aryl compound (I) Ar—X, or a salt thereof, wherein X is 211At, 210At, 123I, 124I, 125I, or 131I. The method involves reacting the aryl boronic acid compound (II) Ar—Y, or a salt thereof, wherein Y is a borono group (—B(OH)2) or an ester group thereof, with a radionuclide selected from 211At, 210At, 123I, 124I, 125I and 131I, in the presence of an oxidizing agent selected from an alkali metal iodide, an alkali metal bromide, N-bromosuccinimide, N-chlorosuccinimide and hydrogen peroxide, in water.

Abstract: An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.

Abstract: A pressure receiving surface inclined to a rotation axis is provided on the side surface of a stir probe of a rotating tool. The pressure receiving surface includes a pressure receiving region which is always perpendicular to a rotation tangential direction in a cross section perpendicular to the rotation axis. In friction stir processing, the stir probe is caused to rotate in a rotation direction B in which the normal direction of the pressure receiving surface is positive. According to this kind of rotating tool, as it has no shoulder, a joint width does not increase even when a stirring region is deep, and also, a plastic flow in a rotation direction is generated by a pressure receiving surface, so that it is possible to reduce the proportion of the plastic flow in the rotation axis direction, and thus possible to suppress an occurrence of burr.

Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.

Abstract: The invention provides a method for producing a solution containing 211At? (astatide ion) at a high radiochemical purity by using 211At obtained by a nuclear reaction as a starting material, including a step of adding a reducing agent to a solution containing an impurity derived from 211At. The invention also provides a solution containing 211At? (astatide ion) at a radiochemical purity of not less than 30%.

Abstract: The present disclosure relates to: an artificial peritoneal tissue comprising a cellular tissue and a mesothelial cell layer that covers the surface of the cellular tissue, wherein the cellular tissue comprises a fibroblast, an extracellular matrix, and a vascular endothelial cell and/or a lymphatic endothelial cell each capable of forming a lumen; and a method for producing the artificial peritoneal tissue.

Abstract: A liquid crystal element (100) refracts and outputs light. The liquid crystal element (100) includes a first electrode (1), a second electrode (2), an insulating layer (21) that is an electric insulator, a resistance layer (22), a liquid crystal layer (23) including liquid crystal, and a third electrode (3). The insulating layer (21) is disposed between each location of the first and second electrodes (1) and (2) and the resistance layer (22) to insulate the first and second electrodes (1) and (2) from the resistance layer (22). The resistance layer (22) has an electrical resistivity higher than that of the first electrode (1) and lower than that of the insulating layer (21). The resistance layer (22) and the liquid crystal layer (23) are disposed between the insulating layer (21) and the third electrode (3). The resistance layer (22) is disposed between the insulating layer (21) and the liquid crystal layer (23).

Abstract: A peptide capable of preventing pathogenic bacteria from colonizing in digestive organs comprises a first domain having an amino acid sequence capable of binding to a minor pilin of IVb fimbriae, and a second domain having an amino acid sequence capable of multimerization, the second domain connect to the first domain via a linker sequence.

Abstract: An agent for treating Fabry disease, external analgesic, and perspiration enhancer in accordance with one embodiment of the present invention each contain rapamycin or a rapamycin derivative.

Abstract: A gyroscope of the present invention includes a moving standing light wave generator to generate three moving standing light waves, an atomic beam source to continuously generate an atomic beam in which individual atoms are in the same state, an interference device that exerts a Sagnac effect through interaction between the atomic beam and the three moving standing light waves and a monitor to detect angular velocity or acceleration by monitoring an atomic beam from the interference device. The atoms are alkaline earth metal atoms, alkaline earth-like metal atoms, stable isotopes of alkaline earth metal atoms or stable isotopes of alkaline earth-like metal atoms.

Abstract: The present invention provides a specific combination of colon cancer markers based on statistical knowledge, which is capable of detecting a larger number of colon cancer patients in an earlier stage while maintaining high specificity. A multiplex colon cancer marker panel comprising a combination of five colon cancer markers of Carcinoembryonic antigen-related cell adhesion molecule 5, Carbohydrate antigen 19-9, Galectin-4, APEX nuclease and Actin-related protein 2. A method for analyzing colon cancer markers using multiplex colon cancer marker panel.

Abstract: An artificial tissue containing pancreatic islet cells, fibroblasts and/or cells capable of differentiating, extracellular matrix, and vascular endothelial cells, in which the fibroblasts and/or the cells capable of differentiating, the extracellular matrix, and the vascular endothelial cells constitute a three-dimensional tissue structure in which a vascular network structure has been formed, and in which the three-dimensional tissue structure contains pancreatic islets constituted by aggregating ten or more of the pancreatic islet cells.

Abstract: A spectroscope for measuring a spectrum of input light includes a fringe former that forms first fringes having a first pitch by splitting the input light, a diffraction grating that disperses each of the first fringes, a moire pattern former that forms a moire pattern by overlaying the first fringes that have been dispersed, on second fringes having a second pitch different from the first pitch, and an image pickup device that measures the spectrum of the input light by detecting the moire pattern. At least one of the fringe former and the moire pattern former includes a cylindrical lens array.

Abstract: A gyroscope of the present invention includes a moving standing light wave generator to generate three moving standing light waves, an atomic beam source to continuously generate an atomic beam in which individual atoms are in the same state, an interference device that exerts a Sagnac effect through interaction between the atomic beam and the three moving standing light waves, and a monitor to detect angular velocity or acceleration by monitoring an atomic beam from the interference device. Each moving standing light wave satisfies an n-th order Bragg condition, where n is a positive integer of 2 or more.

Abstract: In order to provide a naphthobischalcogenadiazole derivative that can be used as an intermediate for producing a naphthobischalcogenadiazole compound into which a fluorine atom has been introduced, the naphthobischalcogenadiazole derivative in accordance with an aspect of the present invention is represented by a formula (I): where each of A1 and A2 is independently an oxygen atom, a sulfur atom, a selenium atom, or a tellurium atom; and each of X1 and X2 is independently a hydrogen atom, a halogen atom, a boronic acid group, a boronic acid ester group, a boronic acid diaminonaphthalene amide group, an N-methyliminodiacetic acid boronate group, a trifluoroborate salt group, or a triolborate salt group.

Abstract: The invention provides a carrier and a method for obtaining, removing, or detecting extracellular membrane vesicle or virus present in a sample. In particular, the invention provides (a) a carrier (a Tim carrier) on which a protein (a Tim protein), selected from a T-cell immunoglobulin and mucin domain-containing molecule-4 (a Tim-4) protein, a Tim-3 protein, and a Tim-1 protein, is bound; (b) a method for obtaining the extracellular membrane vesicle or the virus in the sample; (c) a method for removing the extracellular membrane vesicle or the virus in the sample; (d) a method for detecting the extracellular membrane vesicle or the virus in the sample; (e) a kit for capturing the extracellular membrane vesicle or the virus, comprising the Tim carrier; and f) a kit for capturing the extracellular membrane vesicle or the virus, comprising a reagent containing the Tim protein and a reagent containing the carrier.

Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.

Abstract: Provided is an ink for a 3D printing system having excellent pseudoplasticity. The ink for a 3D printing system includes: silk nanofibers; and a natural polymer and/or a synthetic polymer.

Abstract: The present invention reduces measurement time. A gyroscope of the present invention includes a planar ion trap part, a microwave irradiation part, a laser irradiation part and a measurement part. The planar ion trap part includes two rf electrodes and two DC electrode rows, and forms ion traps that trap one ion on a substrate, a normal direction of the surface of the planar ion trap part corresponds to a z direction. The rf electrodes are disposed in the x direction on the substrate at a predetermined interval. The DC electrode rows are disposed in the x direction on the substrate so as to sandwich the two rf electrodes. The DC electrode rows each include at least five DC electrodes in the x direction. The trapped ions are spaced so as not to interfere with each other. The microwave irradiation part irradiates the ions with ?/2 microwave pulses.

Abstract: The inventors discovered that ectodermal mesenchymal stem cells circulating in peripheral blood that are induced by necrotic tissue damage contribute to the regeneration of damaged tissue. On the basis of this discovery, provided are ectodermal mesenchymal stem cells, a method for producing the same, and a screening method for a substance having pluripotent stem cell inductive activity, the screening method using cells induced by necrotic tissue damage in peripheral blood as an index.